Cyclosporine liposomal (Pari Pharma)

环孢素脂质体（Pari Pharma）

Report date: 2026/01/21 17:00:57

Base Information

Drug NameCyclosporine liposomal (Pari Pharma)
Drug Alias NameCiclosporin inhalationCiclosporin liposomalL-CsA
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Molecular Glue
Mechanisms of ActionCalcineurin inhibitorsMitocliondrial permeability transition pore inhibitorsGlycoproteins inhibitors +[5] 
TargetsCalcineurinMitocliondrial permeability transition poreGlycoproteins +[4] 
Therapy Area/IndicationsRejection of lung transplantationBronchiolitis ObliteransBronchiolitis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesPari Pharma
China Registration ClassN/A

Develop Information

Active CompaniesPari PharmaBreath Therapeutics Inc
Inactive CompaniesUniversity Of Maryland, Baltimore
Active IndicationsBronchiolitis
Inactive IndicationsRejection of lung transplantationBronchiolitis Obliterans

Other Information

ATC CodeL04AD01S01XA18
Related LinksN/A